

International Journal of Pharmaceutical Research & Analysis

e-ISSN: 2249 – 7781 Print ISSN: 2249 – 779X

www.ijpra.com

DEVELOPMENT AND VALIDATION OF A RP- HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF ENALAPRIL MALEATE AND RAMIPRIL IN BULK AND TABLET DOSAGE FORM

Govardhan Bathula*, N.Sriram, M.Jawahar

Smt Sarojini Ramulamma College of Pharmacy, Palamuru University, Mahabubnagar, Andhra Pradesh, India.

ABSTRACT

A simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Enalapril maleate and Ramipril in bulk and tablet dosage form. Chromatographic analysis was performed on an Oyster BDS C18 column (250x 4.6 mm, 5μm) column temperature 65°C with a mixture of buffer A and buffer B in the ratio 50:50 [Buffer A preparation: 2gm of sodium perchloride in 800ml water and add 0.5 ml tri ethyl amine, adjust the pH to 3.6±0.1 with phosphoric acid and add 200 ml of acetonitrile. Buffer B preparation: 2 gm of sodium perchloride in 300 ml water and add 0.5 ml tri ethyl amine, adjust the pH to 2.6±0.1 with phosphoric acid and add 700 ml of acetonitrile] as mobile phase, at a flow rate of 1.0 mL min⁻¹. UV detection was performed at 208 nm. The method was validated for accuracy, precision, specificity, linearity and sensitivity. The retention times of Enalapril maleate and Ramipril were 4.197 and 5.819 min, respectively. Calibration plots were linear over the concentration ranges 5–30 μg mL⁻¹ and 5–30 μg mL⁻¹ for Enalapril maleate and Ramipril, respectively. The Limit of detection was 0.571 and 1.090 μg mL⁻¹ and the quantification limit was 1.733 μg mL⁻¹ and 3.303 μg mL⁻¹ for Enalapril maleate and Ramipril, respectively. The accuracy of the proposed method was determined by recovery studies and found to be 98.06% to 100.47%. Commercial tablet formulation was successfully analyzed using the developed method and the proposed method is applicable to routine analysis of determination of Enalapril maleate and Ramipril in bulk and tablet dosage form.

Keywords: Enalapril maleate, Ramipril, RP-HPLC.

INTRODUCTION

Enalapril is a prodrug which is hydrolysed in the body to Enalaprilat, which is an inhibitor of angiotensin-converting enzyme (ACE). It is indicated for treatment of hypertension, treatment of symptomatic heart failure and prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction (ejection fraction <35%) [1]. Chemically it is ((S)-1-{N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl}-L-proline, (Z)-2-butenedioate (1:1), a derivative of two amino-acids, L-alanine and L-proline (fig.1). It is a white to off-white crystalline, odourless powder which melts in the range of 143–144 °C [2]. ACE is a peptidyldipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II, which stimulates aldosterone secretion by the adrenal cortex. Blocking the

conversion of the angiotensin I to the angiotensin II, leads to a reduction in vasopressin activity and a decrease in peripheral vascular resistance [3, 4]. Oral enalapril is rapidly absorbed, with peak serum concentrations of enalapril occurring within one hour. The extent of absorption of enalapril from oral enalapril tablet is approximately 60%. The absorption of oral enalapril is not influenced by the presence of food in the gastro-intestinal tract. The determination of enalapril has been carried out by numerous analytical methods such as HPLC [5–12], UV spectroscopic method [13].

Ramipril is chemically (2S, 3aS, 6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl] amino} propan oyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid [14], (fig.2).

It is white or almost white crystalline powder. Freely soluble in Methanol, Slightly soluble in Water. Which melts in the range of 109 °C. It is an angiotensinconverting enzyme (ACE) inhibitor, used treat hypertension and congestive heart failure It a prodrug and is converted the active metabolite ramiprilat by liver esterase enzymes. It is an official drug in IP [15] and BP [16]. There are very few analytical methods reported for the estimation of Ramipril which includes RP-HPLC [13-24]. But these methods are sophisticated, expensive and time consuming when compared to simple HPLC method. There is need for a interest to develop simple, accurate, specific, sensitive, precise and reproducible simultaneous RP-HPLC method for the estimation of Enalapril maleate and Ramipril in bulk and its formulation.

MATERIALS AND METHODS

Pure standard of Enalapril maleate and Ramipril (Assigned purity 99.98%) was obtained as a gift sample from Hetero labs Pvt. Ltd, Baddi, India. The gift samples were used as standard without further purification. HPLC grade water, methanol (Qualigens), sodium per chloride, phosphoric acid and tri ethyl amine (S.D. fine chemicals, Mumbai, India), were used throughout the experiment. Commercial pharmaceutical preparation (ENVAS RB (Enalapril, Ramipril), VOLTA (CADILA)) which was claimed to contain 10mg of Enalapril maleate and 10 mg of Ramipril is used in analysis. The chemical structure and purity of the sample obtained was confirmed by TLC, IR, Melting point studies. HPLC grade Acetonitrile from Merck specialties Pvt Ltd, Mumbai. Water HPLC grade was obtained from Rankem laboratories.

Instrumentation and Chromatographic Conditions

High performance liquid chromatograph, HPLC (WATERS 2695), UV-VIS detector was used. Isocratic elution of mobile phase comprising of Chromatographic analysis was performed on a Oyster BDS C18 column (250x 4.6 mm, 5µm) column temperature 65°C, with a mixture of buffer A and buffer B in the ratio 50:50 [Buffer A preparation: 2 gm of sodium perchloride in 800ml water and add 0.5 ml tri ethyl amine, adjust the pH to 3.6±0.1 with phosphoric acid and add 200 ml of acetonitrile. Buffer B preparation: 2gm of sodium perchloride in 300 ml water and add 0.5 ml tri ethyl amine, adjust the pH to 2.6±0.1 with phosphoric acid and add 700 ml of acetonitrile] as mobile phase, at a flow rate of 1.0 mL min⁻¹. UV detection was performed at 208 nm. The retention times of Enalapril maleate and Ramipril were 4.197 and 5.819 min. The column temperature was maintained at ambient and the volume of injection was 20 µL. Prior to injection of analyte, the column was equilibrated for 30 min with mobile phase.

Preparation of mobile phase

The HPLC grade solvents were used for the preparation of mobile phase, isocratic elution of mobile phase comprising of with a mixture of buffer A and buffer B in the ratio 50:50 [Buffer A preparation: 2 gm of sodium perchloride in 800ml water and add 0.5 ml tri ethyl amine, adjust the pH to 3.6±0.1 with phosphoric acid and add 200 ml of acetonitrile. Buffer B preparation: 2 gm of sodium perchloride in 300 ml water and add 0.5 ml tri ethyl amine, adjust the pH to 2.6±0.1 with phosphoric acid and add 700 ml of acetonitrile] as mobile phase and filtered before use through a 0.45μm membrane filter, sonicated and pumped from the solvent reservoir to the column at a flow rate of 1 mL min⁻¹.

Standard solution

Standard stock solutions 1 mg mL-1 of Enalapril maleate and Ramipril were prepared in mobile phase and further diluted in mobile phase. The working standard solutions were prepared in mobile phase to contain mixture of Enalapril maleate and Ramipril in over the linearity range from 5-30 µg mL-1 and 5-30 µg mL-1.

Assay in formulation

Twenty tablets each containing and their average weight was calculated. The tablet were crushed to furnish a homogeneous powder and a quantity equivalent to one tablet were weighed in to a 100 mL volumetric flask, dissolve in mobile phase, sonicated for about 15 min and then made up to volume with mobile phase. The solution was stirred for 10 min using a magnetic stirrer and filtered into a 100 mL volumetric flask through 0.45 µm membrane filter. The residue was washed 3 times with 10 mL of mobile phase, and then the volume was completed to 100 mL with the same solvent. Further add mobile phase to obtain an expected concentration of 10 µg mL-1 Enalapril maleate and 10 µg mL-1 Ramipril. All determinations were conducted in triplicate.

RESULTS AND DISCUSSION

The proposed HPLC method required fewer reagents and materials and it is simple and less time consuming. This method could be used in quality control test in pharmaceutical industries. The chromatogram of Enalapril maleate and Ramipril were shown in (Fig.3). There was clear resolution between Enalapril maleate and Ramipril with retention time of 4.197 and 5.819 minutes, respectively.

Linearity

The response was determined to be linear over the range of $5\mu g$ mL-1 to $30\mu g$ mL-1 (5, 10, 15, 20, 25, 30) for Enalapril maleate and 5-30 μg mL-1 (5, 10, 15, 20, 25, 30) for Ramipril. The solutions were injected into HPLC system. Each of the concentration was injected to get reproduciable response. The run time was 15 min and the peak areas were measured (Table 1 & 2). The calibration

curve was plotted as concentration of the respective drug versus the response at each level. The purposed method was evaluated by its correlation coefficient and intercept value calculated by statistical study. They were represented by the linear regression equation (Fig 4 and 5 calibration curve).

 $Y_{Enalapril} = 53087x - 98013$ Coefficient of correlation (r^2) value = 0.999

 $Y_{Ramipril} = 65905x - 16789$ Coefficient of correlation (r²) value = 0.999

Accuracy

The accuracy is the closeness of the measured value to the true value for the sample. Accuracy was found out by recovery study from prepared solution (three replicates) with standard solution, of the label claim. Aliquots of 50%, 100%, 150% wt of sample drug solution were pipetted into each of three volumetric flasks. To this 5ml of Enalapril standard drug solution of 200 µg mL-1 was added to each volumetric flask respectively. To this 5mL of Ramipril standard drug solution of 200µg mL-1 was added to each volumetric flask respectively. The volume was made up to 100 mL with mobile phase. 20 µL of each solution was injected and chromatograms were recorded. The range was found between 98.06 % to 100.47 % respectively. The values of recovery justify the accuracy of the method. The % recovery values were obtained within the standard limit which confirms that the method is accurate and free from any positive or negative interference of the excipients (Table 3).

Limit of Detection and Quantification

Limit of detection is determined by the analysis of samples with known concentrations of analyte and by establishing the minimum level at which the analyte can be reliably detected. The detection limit (LOD) and quantitation limit (LOQ) may be expressed as:

L.O.D. = 3.3(SD/S)L.O.Q. = 10(SD/S)

Where, SD = Standard deviation of the response, S = Slope of the calibration curve. The slope S may be estimated from the calibration curve of the analyte.

The LOD was found to be 0.571 μ g mL-1 and 1.090 μ g mL-1 and LOQ was found to be 1.733 μ g mL-1 and 3.303 μ g mL-1 for Enalapril and Ramipril respectively which represents that sensitivity of the method is high.

Precision

Table 1. For Peak Area of Enalapril maleate

| Conc μg/ml | area |
|------------|----------|
| 0 | 0 |
| 5 | 2431068 |
| 10 | 5161578 |
| 15 | 7885747 |
| 20 | 10589529 |
| 25 | 13206310 |
| 30 | 15781198 |

Repeatability involves analysis of replicates by the analyst using the same equipment and method and conducting the precision study over short period of time while reproducibility involves precision study at different occasions, different laboratories, and different batch of reagent, different analysts, and different equipments. The repeatability study which was conducted on the solution having the concentration of about 10 μ g mL-1 for Enalapril and 10 μ g mL-1 for Ramipril showed a RSD of 0.09 % for Enalapril and 0.17 % for Ramipril. It was concluded that the analytical technique showed good repeatability (Table 4).

Reproducibility and Ruggedness

The ruggedness of an analytical method is determined by analysis of aliquots from homogenous lots by different analysts using operational and environmental conditions that may differ but are still within the specified parameters of the assay. The assay was performed in different condition, different analyst, and different dates (Table 5).

Robustness

The robustness of the method was determined by delibrate changes in the method like alteration in pH of the mobile phase, percentage organic content, changes in the wavelength. The robustness of the method shows that there were no marked changes in the chromatographic parameters, which demonstrates that the method developed is robust.

Specificity

The selectivity of an analytical method is its ability to measure accurately and specifically the analyte of interest in the presence of components that may be expected to be present in the sample matrix. If an analytical procedure is able to separate and resolve the various components of a mixture and detect the analyte qualitatively the method is called selective. It has been observed that there are no peaks of diluents and placebo at main peak's. Hence, the chromatographic system used for the estimation of Enalapril and Ramipril is very selective and specific .Specificity studies indicating that the excipients did not interfere with the analysis. For demonstrating the specificity of the method for drug formulation the drug was spiked and the representative chromatogram (Fig.6)

Table 2. Peak area of Ramipril

| Conc μg/ml | Area |
|------------|----------|
| 0 | 0 |
| 5 | 2967718 |
| 10 | 6325745 |
| 15 | 9721440 |
| 20 | 13133747 |
| 25 | 16235347 |
| 30 | 19641463 |

Table 3. Result of recovery studies

| | Enalapril | Ramipril |
|-----------------|-------------|-------------|
| Accuracy std | 10588754 | 13154765 |
| | 10587895 | 13161276 |
| | 10578943 | 13170432 |
| Avg | 10585197.33 | 13162157.67 |
| Accuracy sample | 10586587 | 13157863 |
| 50% spike | 15720959 | 19763154 |
| | 15821783 | 19778034 |
| | 15830256 | 19768790 |
| Avg | 15790999.33 | 19769992.67 |
| amt.recovered | 49.17 | 50.24 |
| %Recovery | 98.33 | 100.47 % |
| 100% spike | 20825663 | 26358495 |
| | 21031548 | 26364587 |
| | 21041432 | 26370032 |
| Avg | 20966214.33 | 26364371.33 |
| amt.recovered | 98.06 | 100.34 |
| %Recovery | 98.06 | 100.34 % |
| 150% spike | 26760044 | 32893798 |
| | 26762154 | 32893798 |
| | 25770843 | 32891084 |
| Avg | 26431013.67 | 32892893.33 |
| amt.recovered | 149.68 | 149.94 |
| %recovered | 99.79 | 99.96 % |

Table 4a. Results of repeatability analysis

| Enalapril | | |
|-----------|----------|----------|
| S.No. | RT | Area |
| 1 | 3.602 | 10591539 |
| 2 | 3.601 | 10553534 |
| 3 | 3.601 | 10569019 |
| 4 | 3.602 | 10592134 |
| 5 | 3.602 | 10565347 |
| 6 | 3.602 | 10570126 |
| Avg | 3.601667 | 10573617 |
| Stdev | 0.000516 | 15291.34 |
| %RSD | 0.01 | 0.14 |

Table 4b. Results of repeatability analysis

| Enalapril | | | Ramipril | | |
|-----------|----------|----------|----------|----------|---------|
| S.No. | RT | Area | S.No. | RT | Area |
| 1 | 3.608 | 10616395 | 1 | 6.933 | 131700 |
| 2 | 3.603 | 10597338 | 2 | 6.915 | 131750 |
| 3 | 3.604 | 10603294 | 3 | 6.905 | 132043 |
| 4 | 3.606 | 10621453 | 4 | 6.935 | 131657 |
| 5 | 3.602 | 10605438 | 5 | 6.902 | 132115 |
| 6 | 3.602 | 10602543 | 6 | 6.902 | 132121: |
| avg | 3.604167 | 10607744 | avg | 6.915333 | 131898 |
| stdev | 0.002401 | 9200.346 | stdev | 0.01524 | 21769.4 |
| %RSD | 0.07 | 0.09 % | %RSD | 0.22 | 0.17 % |

Table 5. Results of reproducibility

| | Enalapril | Ramipril |
|---|-----------|----------|
| Average Percentage Recovery | 98.71%, | 100.25% |
| SD between set of analysis on same date | 15291.34 | 16712.44 |
| SD between set of analysis on different date | 9200.34 | 21769.45 |
| RSD between set of analysis on same date | 0.14% | 0.13% |
| RSD between set of analysis on different date | 0.09% | 0.17% |

Table 6. Results of system suitability parameters

| S.No. | Parameters | Enalapril values | Ramipril values |
|-------|------------------------------|------------------|-----------------|
| 1. | Theoritical Plates (N) | 4155.00 | 7641.00 |
| 2. | Resolution (Rs) | 5.03 | 12.36 |
| 3. | Tailing factor (<i>Tf</i>) | 1.11 | 1.02 |

Fig. 3. Typical chromatogram showing Enalapril maleate and Ramipril




Fig. 4. Calibration curve for Enalapril




Fig. 5. Calibration curve for Ramipril





Fig. 6. Chromatogram showing Specificity



System Suitability

A binary solution of $10 \mu g$ mL-1of Enalapril and $10 \mu g$ mL-1 of Ramipril (in triplicate) was prepared and same was injected, then the system suitability parameters like resolution factor (Rs), tailing factor (Tf) and theoretical plates (N) were calculated and recorded in Table 6. The values for system suitability parameters showed feasibility of this method for routine pharmaceutical application.

CONCLUSION

The proposed RP-HPLC method is found to be simple, accurate, precise, linear, and specific for quantitative estimation of Enalapril and Ramipril in bulk and its formulation. The proposed RP-HPLC method is cost effective and less time consuming. The values for

system suitability parameters showed feasibility of this method for routine pharmaceutical application. Hence the present HPLC method is suitable for routine assay of Enalapril and Ramipril in raw materials and in pharmaceutical formulations in the quality control laboratories.

ACKNOWLEDGEMENT

The authors are highly thankful to Shree P. Balaraju Smt Sarojini Ramulamma College of Pharmacy, Palamuru University, Mahabubnagar, Andhra Pradesh, India, for providing all the facilities to carry out the work. And thanks to Hetero labs Pvt. Ltd, Baddi, India, for providing a sample of Enalapril maleate and Ramipril as a gift.

REFERENCES

- 1. Anonymous. http://www.medicines.org.uk/EMC/medicine/22427/SPC/Enalapril/
- 2. Ip DP, Brenner GS. In: K. Florey (Ed.) Analytical Profiles of Drug Substances, Academic Press Orlando FL: 1987, 207–243.
- 3. Franz DN, Gennaro AR. Remington. The Science and Practice of Pharmacy, 19th Edition, Mack Publishing Company: Pennsylvania. 2, p 951.

- 4. Warner GT, Perry CM. Ramipril: A review of its use in the prevention of cardiovascular outcomes. *Drugs*, 62, 2002, 1381-1405
- 5. Al-Momani IF. Determination of hydrochloro-thiazide and enalapril maleate in tablet by RP- HPLC. *Turk J Chem*, 25, 2001, 49-54.
- 6. Thongnopnua P, Poeaknapo C. High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical method. *J Pharm Biomed Anal*, 37, 2005, 763-769.
- 7. Tajerzadeh H, Hamidi M. A simple HPLC method for quantitation of enalaprilat. *J Pharma Biomed Anal*, 24, 2001, 675-680.
- Qin XZ, Demarco J, Dominic PI. Simultaneous determination of enalapril, felodipine and their degradation products in the dosage formulation by reversed phase high performance liquid chromatography using a Spherisorb C8 column. J Chromatogr A, 707, 1995, 245–254.
- 9. Safila Naveed, Najma Sultana and Saeed Arayne M. HPLC-UV Method for the Determination of Enalapril in Bulk, Pharmaceutical Formulations and Serum. *Analytical & Bioanalytical Techniques*, 3, 2012, 1-4.
- 10. Mehrdad Hamidi, Hosnieh Tajerzadeh. A simple HPLC method for quantitation of enalaprilat. *Journal of Pharmaceutical and Biomedical Analysis*, 24(4), 2001, 675–680.
- 11. Tamboli AM, Chetan Chavan, Mohite SK. Development and Validation of a RP- HPLC method for simultaneous determination of Amlodipine Besylate and Enalapril Maleate. *Journal of Pharmacy Research*, 3(11), 2010, 2564-2567.
- 12. Marta De Diego, Gloria Godoy, Sigrid Mennickent and Ricardo Godoy. Determined by chemical stability of enalapril maleate drug substance and tablets by a stability-indicating liquid chromatographic method. *International Year of Chemistry*, 34(3), 2011, 450-454.
- 13. Sunil Kumar Dubey, Sandeep Kumar, Rajeev J Mudakavi, Swapnil Deshpande, Akash Kumar Jain. Development and validation of UV-Spectrophotometric method for determination of Enalapril maleate. *International Journal of Advances in Pharmaceutical Sciences*, 1, 2010, 375-380.
- 14. Laurence L Brunton, John S Lazo, Keith Parker. Goodman & Gilman's. The pharmacological basis of therapeutics, 11th Edition, MC Graw Hill Medical publishing division: New Delhi, 2005, p 803.
- 15. Indian Pharmacopoeia. Indian Pharmacopoeia Commission: Ghaziabad. 3, 2010, 2038.
- 16. British Pharmacopoeia. Ph Euro monograph 1590. Medicines and Health care products Regulatory Agency (MHRA): London. 2, 2003, 1609.
- 17. Kalyana Ramu B and Raghubabu K. Development and validation of ramipril estimation from capsules using visible spectrophotometric method. *International Journal of Chemistry Research*, 2(2), 2011, 15-19.
- 18. Priyanka R Patil, Sachin U Rakesh, Pandurang N Dhabale, Kishor B Burade. Simultaneous Estimation of Ramipril and Amlodipine by UV Spectrophotometric Method. rjpt. *Research J. Pharm. And Tech*, 2 (2), 2009, 304-307.
- 19. Srinivasa Rao and Srinivas K, Jan-Feb 2010, RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form. *Indian Journal of Pharmaceutical Sciences*, 72 (1), 2010, 108-111.
- Chintan V. Patel, Amit P. Khandhar, Anandi D. Captain, Kalpesh T. Patel. Validated Absorption Factor Spectrophotometric and Reversed-Phase High-Performance Liquid Chromatographic Methods for the Determination of Ramipril and Olmesartan Medoxomil in Pharmaceutical Formulations. *Eurasian Journal of Analytical Chemistry*, 2(3), 2007.
- 21. Yogesh Gupta. Isocratic rp-hplc-uv method development and validation for the simultaneous estmation of ramipril and telmisartan in tablet dosage form. *Asian Journal of Pharmaceutical and Clinical Research*, 2(4), 2009, 104-111.
- 22. Manju Latha YB, Gowri Sankar D. Isocratic RP-HPLC method development and validation for the simultaneous estmation of ramipril and telmisartan in tablet dosage form. *Inventi Journals: Pharma Ana & Qual Assur*, 2012, 270.
- 23. Sunil Jawla, Jeyalakshmi K, Krishnamurthy T, Kumar Y. Development and Validation of Simultaneous HPLC method for Estimation of Telmisartan and Ramipril in Pharmaceutical Formulations. *International Journal of Pharm Tech Research*, 2(2), 2010, 1625-1633.
- 24. Lakshmi KS and Lakshmi Sivasubramanian. A stability indicating HPLC method for the simultaneous determination of valsartan and ramipril in binary combination. *J. Chil. Chem. Soc*, 55(2), 2010, 223-226.